The drive to help patients motivates scientists across industry, academia and government to boldly search for new cures.

How the biopharmaceutical industry’s expertise, infrastructure, and ability to bear risk enables it to translate years of collaborative research into life-saving products.

NIH, academic medical centers and the pharmaceutical industry are continually conducting research and exploring new ideas to improve understanding of diseases and newly discovered molecules.

Public sector and private sector scientists build on research about certain molecules, exploring promising ideas and developing new hypotheses for how to treat a disease.

Product development companies lead the effort, bringing infrastructure, expertise, time, and resources to translate these ideas into medicines through clinical research. If successful, clinical trials progress and can include thousands of patients. Manufacturing scales up.

After many years and many millions of dollars in research, the company can manufacture the product so it can be delivered to patients.

The journey from the bench to bedside is not guaranteed. In fact, only about 1 in 10,000 potential candidates becomes a medicine.

Each new medicine put in the hands of patients is the product of its own scientific success story.